A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION

• Status: Completed
• Trial end date: 2012-10-01
• Target enrollment: 0
• Participant gender: Male

Summary

The objective of this non-interventional study is to examine whether use of Phosphodiesterase Inhibitors (PDE5s), including use of sildenafil, vardenafil, or tadalafil, triggers the onset of acute NAION.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer; Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
• Treatments: Phosphodiesterase 5 Inhibitors

Criteria

Inclusion Criteria:

• Male aged ≥45 years;

• Experienced abrupt visual change in only 1 eye

Exclusion Criteria:

• Pain determined by an ophthalmologist to be consistent with an inflammatory/arteritic process or optic neuritis;

• History of NAION or optic neuritis.

• Participation in other studies within 60 days prior to entry in the study.